India Pharma Outlook Team | Wednesday, 24 September 2025
The Competition Commission of South Africa approved Torrent Pharmaceuticals' acquisition of a majority interest in JB Chemicals & Pharmaceuticals from international investment firm KKR on September 22, 2025, giving the company a major boost in its strategic expansion plans. This most recent development was disclosed by the firm on September 23, 2025, in an exchange filing.
In its exchange filing dated September 23, the business stated, " this is to advise you that the Competition Commission, South Africa has granted its permission for the transaction on 22nd September, 2025."
The primary business of the Torrent group, Torrent Pharmaceuticals, manufactures and markets pharmaceutical formulations (FDFs) for several therapeutic areas.
In June, it was announced that Torrent Pharmaceuticals Limited and the international investment firm KKR had reached final agreements for Torrent to buy the majority of JB Chemicals and Pharmaceuticals from KKR for an equity valuation of Rs 25,689 crores (on a fully diluted basis). The two companies will then merge. There will be two stages to the transaction's execution
Also Read: Shilpa Medicare Receives EMA Nod for Rivaroxaban Films
A mandatory open offer to buy up to 26% of JB Pharma shares from public shareholders at an open offer price of Rs 1,639.18 per share will follow the acquisition of a 46.39% equity stake (on a fully diluted basis) through a share purchase agreement at a consideration of Rs 11,917 crores (Rs 1,600 per share).
In addition to the aforementioned, Torrent has stated its intention to purchase up to 2.80% of equity shares from specific JB Pharma workers at a price per share equivalent to that of KKR.
